Actinium Pharmaceuticals has forged an agreement with University of California, Davis for the use of its proprietary CD45 antibody radiation-conjugate, apamistamab-I-131, in the institution’s ongoing phase 1/phase 2 clinical trial of stem cell gene therapy for patients with HIV-related lymphoma.

Apamistamab-I-131 (Iomab-B, Actinium Pharmaceuticals) will replace the chemotherapy conditioning used in the gene therapy trial, which will be the first of its kind to incorporate antibody radiation-conjugate (ARC)-based conditioning, according to the manufacturer. The overall goal of the collaboration is to develop an anti-HIV stem cell gene therapy that will simultaneously treat HIV-related lymphoma and develop immune cells that are resistant to HIV in a population of patients with relapsed or refractory HIV-related lymphoma.